By Turna Ray

ViiV Healthcare, GlaxoSmithKline and Pfizer’s joint spin-off venture to market HIV treatments, will include in its pipeline at least two personalized drugs — Epizicom, which combines lamivudine and the genetically targeted abacavir, and the CCR5-antagonist Selzentry.

ViiV Healthcare, which GSK and Pfizer launched last week, is a new company combining the two firms’ HIV divisions and products. The companies first announced the decision to create the spin-off in April.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.